02025.03.02本文字数:713,阅读时长大约2分钟导读:Vertex制药与Verve Therapeutics终止了为期四年的基因治疗合作,合作原计划开发针对肝脏疾病的基因编辑疗法。此次终止凸显了基因治疗领域的高风险性。与此同时,Verve的核心产品VERVE-102正在进行Ib期临床试验,预计2025年第二季度公布初步数据。此外,Verve与Eli Lilly的合作进展也将成为未来的关键...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.